Failure to act on computer-aided detection breast markings in areas judged to be benign or normal by experienced radiologists does not constitute a breach in the standard of care, according to a study in the March issue of Radiology. The researchers
Failure to act on computer-aided detection breast markings in areas judged to be benign or normal by experienced radiologists does not constitute a breach in the standard of care, according to a study in the March issue of Radiology.
The researchers recommend that radiologists follow standard interpretation procedures even when CAD marks a nonspecific finding.
"In the current legal climate, the appearance of a CAD mark at an area that eventually is shown to be malignant has caused much concern among radiologists. The standard of care for recalling a lesion for further investigation should not change based on such a CAD mark," said Dr. R. James Brenner, a lawyer and a clinical professor of radiology at the University of California, Los Angeles.
Brenner and colleagues at Stanford University and R2 Technology collected 493 pairs of mammogram studies. The pairs consisted of an initial negative screening mammogram and a follow-up screening mammogram indicating cancer. The average time between the two mammograms was 14.6 months.
Of the 493 pair, 169 cases (172 areas of cancer) had cancer indications so subtle that either none or only one or two of the five blinded radiologists participating in the study recommended a screening recall. They judged 80% of the 172 areas as having either a benign or normal appearance.
The investigators then examined the subtle findings with a CAD system. It marked 42% of the 172 cancer findings, or:
· 29% of the 82 findings not recalled by any of the radiologists,
· 49% of the 51 findings recalled by one radiologist
· 59% of the 39 findings recalled by two of the five radiologists
"If CAD identifies a significant abnormality that might not have been detected by a radiologist, then its value is straightforward. The degree to which this occurs is thus far unresolved," Brenner said.
A CAD mark does not necessarily reach a level of predictability that would necessitate a recall. But if a truly suspicious lesion is marked and not recalled, the interpreting radiologist would be required to provide a rationale for not recalling, he said.
"This would occur with or without a CAD mark. The same is true for lesions that are marked but are unlikely to represent cancer," he said. "The legal test for the law of negligence is not accuracy, but reasonableness."
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.